Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

 Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 150 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 475 basis points.
September 11, 2026

Vinge advises IK Partners and Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik

 Vinge has advised IK Partners and its portfolio company Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik, a company specialising in refrigeration technology and refrigeration services in southern Sweden. The acquisition strengthens Francks Kylindustri’s position in southern Sweden and broadens the group’s offering within the refrigeration industry.
September 11, 2026

Vinge advises the sellers of Berg Propulsion

 Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 10, 2026